MedTrace Logo

Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma

NCT06916624 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-04-29

No results posted yet for this study

Summary

Study on the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18F-NY104 PET/CT in diagnosing primary, recurrent, and metastatic lesions of renal cell carcinoma; and investigate the effect of oral low-dose CAIX inhibitor (Acetazolamide) on the tissue distribution of 18F-NY104 in renal cell carcinoma patients, particularly in the stomach and kidneys.

Conditions

  • Renal Cell Carcinoma (RCC)
  • Clear Cell Renal Cell Carcinoma (ccRCC)

Interventions

RADIATION

18F-NY104 PET/CT

The radionuclide ¹⁸F will serve as the tracer in this study. NY104 will be labeled with \[¹⁸F\]AlF to form the ¹⁸F-NY104 injection for use in this research.All participants will undergo ¹⁸F-NY104 PET scan.

Sponsors & Collaborators

  • Qianfoshan Hospital

    collaborator OTHER

  • Weifang People's Hospital

    collaborator OTHER

  • Zibo Central Hospital

    collaborator OTHER_GOV

  • Jining Medical University

    collaborator OTHER

  • The Affiliated Hospital of Qingdao University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-12
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06916624 on ClinicalTrials.gov